We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Backgrounds and objectives Clopidogrel, an inhibitor of platelet ADP P2Y12 receptors,
plays an important role in the prevention of stent thrombosis. However, some patients do not …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

Clopidogrel is a thienopyridine derivative with ADP-antagonistic activity and is widely used
for the prevention of ischemic events in patients who have suffered a stroke, non-ST …

A double‐blind crossover study was conducted in four CYP2C19 genotype–defined
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …

Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Background: The P2Y 12 adenosine diphosphate (ADP) receptor blocker, clopidogrel, an
essential drug for the prevention of stent thrombosis after percutaneous coronary …

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

Clopidogrel, a prodrug, must be activated by hepatic cytochrome P450 (CYP) isoenzymes
before being able to irreversibly block the platelet adenosine 5′-diphosphate (ADP) …